In vitro antibacterial activity of DL-8280 and its therapeutic efficacy on respiratory tract infections

Seiichi Aonuma, Kikuo Onuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno, Kosaku Nagai

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)

    Abstract

    Recently, a new oral antibiotic agent, structurally related to nalidixic acid, was synthesized in laboratory of Daiichi Seiyaku Co., Ltd., in Japan. It was shown that this new agent possessed a broad antimicrobial spectrum covering gram-negative cocci and gram-negative bacilli. Minimal inhibitory concentrations (MICs) of the agent against each 20 clinical isolates of S. aureus, E. coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa were determined by use of Dynatech MIC 2000 system. The growth of all the tested strains of S. aureus was inhibited at 0.39 μg/ml of the agent. At a concentration of 0.78 μg/ml, this agent inhibited 95, 90 and 85 per cent of the strains of 5. marcescens, E. coli and E. cloacae, respectively. A concentration of 1.56 μg/ml was required to inhibit 80 per cent of the strains of P. aeruginosa. Sixteen patients suffering from respiratory tract infections received orally 300 to 600 mg of the drug a day. 3 patients who visited only once at the start of the treatment was omitted from the evaluation of therapeutic efficacy of the drug. In remaining 13 patients, 2 showed an excellent response, 9 a good response and 2 a fair response. No undesirable symptoms and signs due to administration of the drug was observed. No abnormality in laboratory findings was noted during and after the treatment with the drug.

    Original languageEnglish
    Pages (from-to)178-184
    Number of pages7
    JournalChemotherapy
    Volume32
    DOIs
    Publication statusPublished - 1984 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'In vitro antibacterial activity of DL-8280 and its therapeutic efficacy on respiratory tract infections'. Together they form a unique fingerprint.

    Cite this